InnoCare Pharma announced that it plans to repurchase 1.4 million shares by December 31, 2025, accounting for 0.08%. The relevant revenue for 2023 was 41.5716 million yuan, and net profit was 17.643 million yuan. There are various batch repurchase arrangements in 2023, including 800,000 shares and 600,000 shares. In addition, it also involves some share-related ratio situations, such as a matter accounting for 0.1%, etc.

InnoCare Pharma announced that it plans to repurchase 1.4 million shares by December 31, 2025, accounting for 0.08%. The relevant revenue for 2023 was 41.5716 million yuan, and net profit was 17.643 million yuan. There are various batch repurchase arrangements in 2023, including 800,000 shares and 600,000 shares. In addition, it also involves some share-related ratio situations, such as a matter accounting for 0.1%, etc.